Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01931033 · ClinicalTrials.gov registry record · NA

An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders

A NA study of Autism Spectrum Disorders and ASD, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
8
Enrollment target
1
Study location

NCT01931033 is a NA study of Autism Spectrum Disorders and ASD that has completed, run by Massachusetts General Hospital. The registered enrollment target is 8 participants, below the 168-participant average among 20 other Autism Spectrum Disorders trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01931033, a NA study of Autism Spectrum Disorders and ASD, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

This study is an 8-week open-label trial testing oxytocin nasal spray (Syntocinon) as a treatment for social impairment in adolescents with autism spectrum disorders (ASD). We hypothesize that oxytocin nasal spray will be safe, tolerable, and effective in improving the core symptoms of autism spectrum disorders in adolescents ages 11-17.

Interventions

  • DRUG Intranasal Oxytocin

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2013-10
Est. Completion 2016-02-22
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT01931033

The ClinicalTrials.gov registry entry for NCT01931033 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 168-participant average among 20 other Autism Spectrum Disorders trials with a reported enrollment target (95% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Autism Spectrum Disorders appearing as the primary indexed condition, and to 1 intervention - of which Intranasal Oxytocin is the first listed.

NCT01931033 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01931033 about?

NCT01931033 is a clinical study titled "An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders". This study is an 8-week open-label trial testing oxytocin nasal spray (Syntocinon) as a treatment for social impairment in adolescents with autism spectrum disorders (ASD). We hypothesize that oxytocin nasal spray will be safe, tolerable, and effective in improving the core symptoms of autism spectr...

What is the current status of trial NCT01931033?

This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2013-10. Estimated completion is 2016-02-22.

What conditions does trial NCT01931033 study?

This clinical trial studies the following conditions: Autism Spectrum Disorders, ASD, PDD, Pervasive Developmental Disorders.

What interventions are being tested in trial NCT01931033?

The interventions under investigation include: Intranasal Oxytocin (DRUG).

Who is sponsoring clinical trial NCT01931033?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01931033 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autism Spectrum Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.